01/15/14 ERIE, Pa. Dr. Steven A. Curley has been named Chief of the Division of Surgical Oncology and Associate Director for clinical affairs in the Dan L. Duncan Cancer Center at Baylor College of Medicine in Houston, Texas. Last summer, Dr. Curley informed Kanzius Cancer Research Foundation that he was considering a new leadership position and subsequently, the official announcement of his move to Baylor was made on October 1st, 2013 by the institution.
“The Kanzius Foundation feels that this is an exciting professional move for Dr. Curley and for the Kanzius research team, as Baylor College of Medicine offers considerable more space and enhanced access to a state-of-the-art facility; this will ultimately benefit the advancement of the research we are funding,” explains executive director, Mark A. Neidig, Sr.
The equipment that the Kanzius Foundation has previously granted for research in the Kanzius Lab at M.D. Anderson Cancer Center has been moved with Dr. Curley to the lab facilities at Baylor College of Medicine. In December of 2013, $1.6 million was granted to Dr. Curley and Baylor for research in 2014; this includes funding for fifteen staff members following Dr. Curley and a new $587,000 Nikon FN1 Upright Microscope that allows researchers to track the effects of the Kanzius RF (radiofrequency) field on blood flow in live animals with malignant tumors and the distribution of drugs and nanoparticles within the tumor.
“The research is progressing faster than ever towards the FDA,” said Dr. Curley, lead Kanzius researcher. “With the recent move to Baylor College of Medicine and the Kanzius Foundation’s willingness to fund my staff and this crucial Nikon FN1 microscope, our research is right on track to human trials.”
Although there has been no official, public announcement, Kanzius Cancer Research Foundation was notified on January 3, 2014 that there are new owners of the intellectual properties for the Kanzius Noninvasive Radiowave Cancer Treatment and RF devices. Neidig adds, “Dr. Curley assures us that going to the FDA early this year is their first priority.” The Kanzius Treatment was previously the intellectual property of ThermMed, LLC, a company created by the late John Kanzius.